Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry

Clinica Chimica Acta

Volumn 412, Issue 21-22, 2011, Pages 1978-1982

  Park, Young Seung ^a   Yoo, Chong Woo ^b   Lee, Seok Cheol ^b   Park, Sang Jae ^b   Oh, Jae Hwan ^b   Yoo, Byong Chul ^b   Paik, Seung Sam ^c   Lee, Kyeong Geun ^c   Jin, So Young ^d   Kim, Song Cheol ^e   Kim, Kwang Pyo ^f   Kim, Young Hwan ^a,g   Choi, Dongho ^d   Kim, Hark Kyun ^b  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b National Cancer Center   (South Korea)

^c Hanyang University   (South Korea)

^d Soonchunhyang University   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Konkuk University   (South Korea)

^g Chungnam National University   (South Korea)

Author keywords

Cholangiocarcinoma; Lipid; MALDI

Indexed keywords

ALPHA CYANO 4 HYDROXYCINNAMIC ACID; GENTISIC ACID; LIPID;

ARTICLE; BILE DUCT CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; GALLBLADDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID ANALYSIS; LIPID METABOLISM; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; VALIDATION STUDY;

ADULT; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 80051677819     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.008     Document Type: Article

References (21)

1. Bonney G.K., Craven R.A., Prasad R., Melcher A.F., Selby P.J., Banks R.E. Circulating markers of biliary malignancy: opportunities in proteomics?. Lancet Oncol 2008, 9:149-158.
2. Hurlimann J., Gardiol D. Immunohistochemistry in the differential diagnosis of liver carcinomas. Am J Surg Pathol 1991, 15(3):280-288.
3. Farid S.G., Craven R.A., Peng J., et al. Shotgun proteomics of human bile in hilar cholangiocarcinoma. Proteomics Mar 11 2011, [Epub ahead of print].
4. Dos Santos A., Court M., Thiers V., et al. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol Cell Proteomics 2010, 9(9):1991-2004.
5. Srisomsap C., Sawangareetrakul P., Subhasitanont P., et al. Proteomic analysis of cholangiocarcinoma cell line. Proteomics 2004, 4(4):1135-1144.
6. Stoeckli M., Chaurand P., Hallahan D.E., Caprioli R.M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001, 7:493-496.
7. Yanagisawa K., Shyr Y., Xu B.J., et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003, 362(9382):433-449.
8. Schwartz S.A., Weil R.J., Thompson R.C., et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005, 65(17):7674-7681.
9. Kim H.K., Reyzer M.L., Choi I.J., et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010, 9(8):4123-4130.
10. Jackson S.N., Woods A.S. Direct profiling of tissue lipids by MALDI-TOFMS. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(26):2822-2829.
11. Shanta S.R., Zhou L.H., Park Y.S., Kim Y.H., Kim Y., Kim K.P. Binary matrix for MALDI imaging mass spectrometry of phospholipids in both ion modes. Anal Chem 2011, 83(4):1252-1259.
12. Meriaux C., Franck J., Wisztorski M., Salzet M., Fournier I. Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids. J Proteomics 2010, 73(6):1204-1218.
13. Momchilova A., Markovska T., Pankov R. Phospholipid dependence of membrane-bound phospholipase A2 in ras-transformed NIH 3T3 fibroblasts. Biochimie 1998, 80(12):1055-1062.
14. Momchilova A.B., Petkova D.H., Koumanov K.S. Phospholipid composition modifications influence phospholipase A2 activity in rat liver plasma membranes. Int J Biochem 1986, 18:945-952.
15. Hilvo M., Denkert C., Lehtinen L., et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res Mar 17 2011, [Epub ahead of print].
16. Janardhan S., Srivani P., Sastry G.N. Choline kinase: an important target for cancer. Curr Med Chem 2006, 13(10):1169-1186.
17. Gallego-Ortega D., Ramirez de Molina A., Ramos M.A., et al. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 2009, 4(11):e7819-e7829.
18. Ramírez de Molina A., Rodríguez-González A., Gutiérrez R., et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296(3):580-583.
19. Glunde K., Jie C., Bhujwalla Z.M. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004, 64:4270-4276.
20. Iorio E., Mezzanzanica D., Alberti P., et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005, 65:9369-9376.
21. Park S.Y., Kim B.H., Kim J.H., Lee S., Kang G.H. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007, 131(10):1561-1567.